Product Description
A novel therapeutic small molecule inhibitor of plasminogen activator inhibitor 1 (PAI-1) as a potential treatment for diffuse cutaneous systemic sclerosis with associated interstitial lung disease (dcSSc-ILD). MDI Therapeutics has identified a highly effective, orally active, small molecule inhibitor of PAI-1 with efficacy in multiple models of fibrotic disease, including pulmonary fibrosis and SSc. (Sourced from: https://www.sbir.gov/sbirsearch/detail/1686893)
Mechanisms of Action: PAI-1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MDI Therapeutics, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MDI-2517-01-001 | P1 |
Recruiting |
Healthy Volunteers |
2024-09-01 |